Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

Journal of Evidence-Based Dental Practice

Volumn 9, Issue 1, 2009, Pages 13-15

  Migliorati, Cesar A ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61349161837     PISSN: 15323382     EISSN: 15323390     Source Type: Journal    
DOI: 10.1016/j.jebdp.2008.12.014     Document Type: Note

References (17)

1. Black D., Delmas P., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 18 (2007) 1809-1822
2. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17 1 (2000) 1-45
3. Edwards B., and Migliorati C. Osteoporosis and its implications for dental patients. J Am Dent Assoc 139 5 (2008) 545-552 quiz 625-6
4. Liberman U., Weiss S., Bröll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 22 (1995) 1437-1443
5. Harris S., Watts N., Genant H., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 14 (1999) 1344-1352
6. Neer R., Arnaud C., Zanchetta J., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 19 (2001) 1434-1441
7. Goss A. Bisphosphonate-associated osteonecrosis of the jaws. Climacteric 10 1 (2007) 5-8
8. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 9 (2003) 1115-1117
9. Migliorati C. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21 22 (2003) 4253-4254
10. Ruggiero S., Mehrotra B., Rosenberg T., and Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 5 (2004) 527-534
11. Migliorati C., Casiglia J., Epstein J., Jacobsen P., Siegel M., and Woo S. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136 12 (2005) 1658-1668
12. Migliorati C. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99 2 (2005) 135
13. Smith M. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31 Suppl 3 (2005) 19-25
14. Woo S., Hellstein J., and Kalmar J. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 10 (2006) 753-761
15. Grbic J., Landesberg R., Lin S., et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139 1 (2008) 32-40
16. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 3 (2007) 369-376
17. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 137 8 (2006) 1144-1150. http://www.ada.org/prof/resources/topics/osteonecrosis.asp Updated Aug 2008, Available at: http://www.ada.org/prof/resources/topics/osteonecrosis.asp. Accessed November 24, 2008.